Host Immune System & Intestinal Epithelial Barrier

The host immune system and intestinal epithelial barrier represent a complex physiological interface essential for maintaining homeostasis and defending against pathogens. The intestinal epithelial barrier consists of a single layer of cells joined by tight junctions, which physically separates the luminal contents from the underlying mucosal immune system (Vancamelbeke & Vermeire, 2017, Expert Rev Gastroenterol Hepatol). This system regulates the transport of nutrients and water while preventing the translocation of harmful bacteria and toxins (Turner, 2009, Nat Rev Immunol). Dysregulation of this barrier, often referred to as "leaky gut," allows for the activation of the gut-associated lymphoid tissue (GALT), leading to chronic inflammation (Mehandru & Colombel, 2021, Immunity). This interaction is central to the pathogenesis of various conditions, including inflammatory bowel disease (IBD) and celiac disease (Okumura & Takeda, 2017, Exp Mol Med). Therapeutic strategies often focus on specific molecular components within this system, such as cytokines or adhesion molecules, to restore barrier function and dampen aberrant immune responses. Drugs like vedolizumab and infliximab target specific pathways within this system to achieve mucosal healing and clinical remission.

Other names

Intestinal mucosal barrierGut-immune axisGastrointestinal barrierGut-associated lymphoid tissue (GALT) interface

Therapeutic intervention typically involves the modulation of specific molecular components within the system, such as neutralizing pro-inflammatory cytokines (e.g., TNF-alpha), inhibiting leukocyte trafficking (e.g., alpha-4 beta-7 integrin), or blocking intracellular signaling pathways (e.g., JAK-STAT) to restore barrier integrity and immune homeostasis.